EEC 2022 symposium: AADC deficiency differential diagnosis and management: The clinician and caregiver experience

This symposium from the 14th EEC Congress, held in Geneva, Switzerland 2022, provides real-world insights into the caregiver and clinician perspective of the diagnosis and management of aromatic L-amino acid decarboxylase (AADC) deficiency

• Explore red flag signs and symptoms of AADC deficiency 
• Understand key diagnostic tests and the challenges of differential diagnoses 
• Review the current therapeutic landscape* of AADC deficiency, including key clinical data and patient outcomes 
• Learn more about the caregiver burden associated with AADC deficiency

*Product-related information will be discussed.

▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.

Eladocagene exuparvovec is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype in the European Member States, Iceland, Liechtenstein, Norway, and Northern Ireland.

Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for eladocagene exuparvovec is available here. Please refer to your local country guidance for more information.

This symposium was developed and funded by PTC Therapeutics for EEC 2022. It is not part of the official program at EEC 2022.